A message from the President

Sosei was established in 1990 with the vision to create a global biotechnology company, anchored in Japan, capable of discovering, developing and delivering new medicines that could contribute to improving the health and quality of life of people around the world.

In recent years, we have made significant progress in building the foundations of a business that has the potential to reach this vision, and to deliver consistent global business growth. This has been achieved through our listing on the Mothers Section of the Tokyo Stock Exchange, acquiring the British companies Arakis and Heptares Therapeutics, and through entering into partnerships with major global pharmaceutical companies.

The acquisition of Arakis has provided a valuable and long term revenue stream through products licensed to and subsequently developed and marketed by Novartis for treating respiratory diseases. In February 2015, we acquired Heptares enabling Sosei to generate our own sustainable pipeline of new drug candidates in multiple disease areas. Heptares has developed an exciting and powerful platform technology (StaR® Technology), which enables precise structure-based drug design for G protein-coupled receptors (GPCRs), arguably the most important target class for pharmaceutical development. These acquisitions have been transformational for Sosei and have since contributed to the company achieving tremendous advances in R&D and in forming partnerships around our pipeline and technology with five major global pharmaceutical companies Novartis, Allergan, AstraZeneca, Pfizer and Teva.

Heptares is now firmly at the core of Sosei's organic growth strategy as we look to strengthen our science and technology leadership, expand our proprietary pipeline and accelerate new drug development. In parallel, the search for new M&A opportunities that could further accelerate or strengthen Sosei's ability to achieve its vision will continue and will remain an important part of our overall growth strategy.

We believe that Sosei has an exciting future based on world-leading science and innovation and is strongly positioned for further growth. I look forward to being able to share the excitement of Sosei's progress with you all, and am grateful for your continued support.

Peter Bains
Representative Executive Officer, CEO
Sosei Group Corporation